<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041868</url>
  </required_header>
  <id_info>
    <org_study_id>02794918.1.0000.5259</org_study_id>
    <nct_id>NCT05041868</nct_id>
  </id_info>
  <brief_title>Rehabilitation Program in Patients With Scleroderma</brief_title>
  <official_title>Physical Rehabilitation in Women With Scleroderma: Effects on Pulmonary Function, Lung Ultrasound, Muscle Function, Hand Functional, Functional Capacity, and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitário Augusto Motta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitário Augusto Motta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scleroderma (or Systemic Sclerosis - SSc) is one of the most neglected diseases worldwide,&#xD;
      according to the World Health Organization. In the adult population with SS, the systemic&#xD;
      effects of the disease, such as respiratory and peripheral muscle dysfunction, cause a&#xD;
      decrease in quality of life. As a consequence, there is a concern about functional&#xD;
      rehabilitation, since the aging of this population is already a reality. Thus, the objective&#xD;
      of this project is to evaluate the effects of functional rehabilitation on functional&#xD;
      capacity and quality of life in women over 18 years of SS. In this longitudinal intervention&#xD;
      study, patients will be submitted to a three-month rehabilitation program. Before and after&#xD;
      the intervention, patients will be submitted to the following assessments: Cochin Hand&#xD;
      Functional Scale (CHFS), Short-Form 36 Health Survey (SF-36); Scleroderma Health Assessment&#xD;
      Questionnaire Disability Index (SHAQ-DI); lung function; lung ultrasound; handgrip; Glittre&#xD;
      Activities of Daily Living test. Thus, it is expected that patients with SS will benefit&#xD;
      significantly, with a consequent improvement in musculoskeletal function and , functional&#xD;
      capacity and health-related quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current epidemiological context, chronic diseases affect very specific and neglected&#xD;
      populations. In addition to their rarity, these diseases are characterized by a progressive&#xD;
      increase in the life expectancy of their patients and important functional limitations due to&#xD;
      their multisystemic character. In this context, there is Systemic Sclerosis - SSc (or&#xD;
      Scleroderma), which presents peculiar clinical and functional aspects that limit the&#xD;
      activities of daily living (ADL) of patients. Although the focus of SSc treatment is the&#xD;
      clinical control of the disease, a new perspective must be given to the aspect of functional&#xD;
      rehabilitation. Therefore, this study proposes a therapist-oriented home rehabilitation&#xD;
      program (TOHR) for these patients. Considering that in SSc the hands are predominantly&#xD;
      affected, and that functional incapacity of the hands is the main component of global&#xD;
      incapacity in this population, the ADL-Glittre test has been used as a submaximal functional&#xD;
      capacity test as it involves lower and upper limbs, as well as diversified tasks, coming&#xD;
      closer to the activities that the individual does in its usual environment. Thus, the present&#xD;
      study aims to evaluate the effects of a TOHR program on the functional capacity of patients&#xD;
      with SSc, through the ADL-Glittre test, considering the impact of hand function, peripheral&#xD;
      muscle strength, pulmonary function and quality of life. For this, women with SSc will be&#xD;
      evaluated, submitted to the following tests: Cochin Hand Functional Scale, Short-Form 36&#xD;
      Health Survey; Scleroderma Health Assessment Questionnaire Disability Index; handgrip&#xD;
      dynamometry; impulse oscillometry technique; spirometry; lung ultrasound and ADL-Glittre&#xD;
      test. Additionally, patients will undergo a 12-week TOHR protocol. At the end of this period,&#xD;
      all evaluations will be repeated. This will be a prospective, longitudinal study, with&#xD;
      quantitative assessment of sample data. The aim of the study is to support the applicability&#xD;
      of a TOHR program in women with SSc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Women with Scleroderma will use a booklet-guided rehabilitation program that lasts three months (3 times per week with a duration of 60 minutes per session). Consisting of stretching, warm-up and cool-down exercises, muscle strengthening (flexion, extension, adduction, and abduction movements in exercises involving open and closed kinetic chains), endurance exercises, aerobic training, balance training and proprioception. The patient will be evaluated at 2 different timepoints (baseline and after 12 weeks of training). The physiotherapist contacts the patient by phone weekly to follow the progression of the treatment. Before and after the intervention, patients will be submitted to the following assessments: Cochin Hand Functional Scale (CHFS), Short-Form 36 Health Survey (SF-36); Scleroderma Health Assessment Questionnaire Disability Index (SHAQ-DI); lung function; lung ultrasound; handgrip; Glittre Activities of Daily Living test.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional capacity through the Glittre Activities of Daily Living test (ADL-Glittre test) before and after the execution of the treatment plan</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Performed as proposed by Skumlien et al. (2006), the participant must complete 5 laps in the shortest possible time. The test consists of carrying a backpack containing a 2.5 kg weight completing a circuit with the following activities. The participant rises from a seated position and walks on a 10-m flat course, interposed halfway by a stairway with 2 steps to ascend and 2 to descend. After completing the course, the individual approaches a 2-teir shelf containing 3 objects weighing 1 kg each, placed on the highest shelf (shoulder height), that must be moved 1 by 1 to the bottom shelf (waist height) and then down to the floor. Then, the objects are placed on the bottom shelf again and finally on the top shelf. Then, the individual turns and walks back over the course; immediately after completion of 1 lap, another lap is started, completing the same circuit. The instructions are standardized, and there is no incentive during the test. Two tests are performed with a minim.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral muscle function before and after the execution of the treatment plan</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Isometric handgrip strength (IHGS) was measured using a hydraulic isometric dynamometer (SH5001, Saehan Corporation, Korea) with the hand on the dominant side of the body. Participants were comfortably seated in a chair with no arm rest, with the feet flat on the floor and hips and knees flexed at 90°. The shoulder was adducted, the elbow was flexed at 90º, and the forearm was in a neutral position; the wrist position could vary between 0-30º of extension and 0-15º of ulnar deviation. The participants were then instructed to perform 3 maximum voluntary contractions with a 60-s interval in between. The tests followed the standards established by the American Society of Hand Therapists. The highest recorded value among the 3 measurements was considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cochin Hand Functional Scale (CHFS)</measure>
    <time_frame>twelve weeks</time_frame>
    <description>The CHFS was used to assess the level of hand ability and functionality in the performance of daily activities. The CHFS contains 18 items concerning ADLs that require manual skills, such as cooking, dressing and personal hygiene. This scale takes approximately 3 min to complete and considers only the experiences of the individual during the past month. Each item has 6 possible answers, as follows: without difficulty (0); with very little difficulty (1); with some difficulty (2); with much difficulty (3); nearly impossible to do (4); and impossible to do (5). The score is the sum of all items and ranges from 0 to 90; the higher the score is, the greater the hand dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related to activities of daily living through the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) before and after the execution of the treatment plan.</measure>
    <time_frame>twelve weeks</time_frame>
    <description>The 36-Item Short Form Survey (SF-36) is an oft-used, well-researched, self-reported measure of health. It stems from a study called the Medical Outcomes Study. Patients or individuals are asked to fill out the questionnaire (tick boxes) by themselves and then it is scored by a researcher. It contains the 36 questions and answers in the bodily pain and general health domains.Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL. Two component scores can also be tallied; a physical component summary and a mental component summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Tests before and after the execution of the treatment plan</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Impulse oscillometry (IOS) will use an impulse oscillometer (Quark i2m, Cosmed, Rome, Italy). IOS measures the respiratory system impedance (Zrs) composed of the respiratory system resistance and the respiratory system reactance. The minimum acceptable coherence values will be those ≥ 0.9 Hz. (RIBEIRO et al, 2018) Participants will also perform spirometry (VT 130 SL, Codax Ltda, Rio de Janeiro, Brazil), using standardization made by the American Thoracic Society/European Respiratory Society. The predicted values of FVC, expiratory volume in one second (FEV1) and forced expiratory flow between 25-75% of FVC (FEF25-75%) will be calculated according to the equations of Pereira et al (2007) and the results will be expressed as percentages of the predicted values. Obstructive disorder will be defined by an FEV1/FVC ratio &lt;70%, while a restrictive disorder will be inferred by a FVC &lt;80% predicted in the absence of reduced expiratory flows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung ultrassound before and after the execution of the treatment plan</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Using an Aplio XG Aplio XG equipment (Toshiba Medical Systems, Tokyo, Japan), with a 7.5-10 MHz multifrequency linear transducer or a 3.5-5 MHz convex transducer in B mode, the USP exams will be performed on the same day as the TFP. Following a 12-zone protocol and with participants in a seated position, the USP exams will be performed in 6 areas of each hemithorax (two anterior, two lateral and two posterior). USP images will be examined for the evaluation of the following signs: B lines &gt; 2, coalescent B lines and subpleural consolidations. In order to classify the lung injury, in each of these 6 areas, weights ranging from 1 to 3 will be assigned for each finding in the USP, as follows: 1 = lines B &gt; 2; 2 = coalescent B lines; and 3 = subpleural consolidations). The sum of all 6 areas evaluated at USP will represent the aeration score, which may vary between 0-18 points. (SOUMMER et al., 2012; TUNG-CHEN et al., 2020)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability assessment using the Scleroderma Health Assessment Questionnaire Disability Index (SHAQ-DI) before and after the execution of the treatment plan</measure>
    <time_frame>twelve weeks</time_frame>
    <description>The SHAQ-DI will be used to assess the participants' level of physical function. This questionnaire includes questions related to fine movements of the upper extremities and motor activities of the lower limbs (BRUCE &amp; FRIES, 2003). There are 20 questions divided into 8 categories that represent a comprehensive set of functional activities performed in the last 7 days, including the ability to dress, stand up, eat, walk, perform personal hygiene, reach or grab something, and perform usual activities . To quantify the values found, the SHAQ-DI has a 26 score ranging from 0 (no disability) to 3 (maximum disability). The total score is the average of the scores of the 8 categories.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Scleroderma</condition>
  <condition>System; Sclerosis</condition>
  <condition>Muscle Strain</condition>
  <condition>Physical Disability</condition>
  <condition>Quality of Life</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The program comprises the practice of warm-up, muscle strengthening with free weights and with their own body weight against the action of gravity for the main muscular groups, balance control training, aerobic training, and relaxation exercises. The proposal consists of 3 weekly sessions, for 12 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <description>After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with Scleroderma, older than 18 years&#xD;
&#xD;
          -  Clinical stability&#xD;
&#xD;
          -  Signature of the Informed Consent Term (TCLE)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inability to perform the Glittre Activities of Daily Living test&#xD;
&#xD;
          -  Patients who have cognitive impairment by mini mental state examination (MEEN).&#xD;
&#xD;
          -  Abandonment of treatment of scleroderma during the application of the protocol.&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; 180/100 mmHg with medication use)&#xD;
&#xD;
          -  Use of psychotropic drugs&#xD;
&#xD;
          -  Any significant limitations due to osteoarthropathy&#xD;
&#xD;
          -  History of surgery in the previous six months with exercise restriction&#xD;
&#xD;
          -  IPAQ with very active classification&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Scleroderma is more frequent in females than in males.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samantha Alegria, MsC</last_name>
    <phone>+55 (21) 992936572</phone>
    <email>s.gomesdealegria13@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnaldo Lopes, PhD</last_name>
    <phone>+55 (21) 25762030</phone>
    <email>agnaldolopes.uerj@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Universitário Augusto Motta</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22745271</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnaldo Lopes, PhD</last_name>
      <phone>+55 (21) 25762030</phone>
      <email>agnaldolopes.uerj@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1590/S1807-59322011000500004</url>
    <description>Translation, cultural adaptation and reproducibility of the Cochin Hand Functional Scale questionnaire for Brazil</description>
  </link>
  <link>
    <url>http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;src=google&amp;base=LILACS&amp;lang=p&amp;nextAction=lnk&amp;exprSearch=296502&amp;indexSearch=ID</url>
    <description>Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36) / Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure</description>
  </link>
  <link>
    <url>https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwiYpu-H8tPwAhW-qJUCHRUjANgQFjAAegQIAhAD&amp;url=http%3A%2F%2Fwww.saude.ufpr.br%2Fportal%2Flabsim%2Fwp-content%2Fuploads%2Fsites%2F23%2F2016%2F07%2FSuple_139_45_11-Espirometria.pdf&amp;usg=AOvVaw1UGXp51DUZsTOXA2rjdVOy</url>
    <description>Pereira CAC. Espirometria. J Bras Pneumol. 2002; 28(Supl. 3): 1-82.</description>
  </link>
  <link>
    <url>https://www.who.int/classifications/drafticfpracticalmanual.pdf</url>
    <description>World Health Organization. How to use the ICF: A practical manual for using the International Classification of Functioning, Disability and Health (ICF). Exposure draft for comment. October 2013. Geneva: WHO.</description>
  </link>
  <reference>
    <citation>Alhajeri H, Hudson M, Fritzler M, Pope J, Tatibouet S, Markland J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larché M, Baron M. 2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2015 Apr;67(4):582-7. doi: 10.1002/acr.22451.</citation>
    <PMID>25233870</PMID>
  </reference>
  <reference>
    <citation>Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara LM, Morovic-Vergles J, Denton C, Hinrichs R, Van den Hoogen F, Damjanov N, Kötter I, Ortiz V, Heitmann S, Krasowska D, Seidel M, Hasler P, Van Laar JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wislowska M, Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A, Cossutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL, Steinbrink K, Herrick A, Müller-Ladner U, Dinc A, Scorza R, Sondergaard K, Indiveri F, Nielsen H, Szekanecz Z, Silver RM, Antivalle M, Espinosa IB, García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F, Tuvik P, Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M, Sunderkötter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J, Zeni S, Nash P, Mouthon L, De Keyser F, Duruöz MT, Cantatore FP, Strauss G, von Mülhen CA, Pozzi MR, Eyerich K, Szechinski J, Keiserman M, Houssiau FA, Román-Ivorra JA, Krummel-Lorenz B, Aringer M, Westhovens R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S, Granel B, Valderílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo Machado X, Pileckyte M, Stebbings S, Mathieu A, Tulli A, Tourinho T, Souza R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D, Francisco Marques Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed W, Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C, Vonk M, Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Hachulla E, Furst DE. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 Jul;37(7):1488-501. doi: 10.3899/jrheum.091165. Epub 2010 Jun 15.</citation>
    <PMID>20551097</PMID>
  </reference>
  <reference>
    <citation>Barsotti S, Stagnaro C, d'Ascanio A, Della Rossa A. One year in review 2016: systemic sclerosis. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):3-13. Epub 2016 Jul 18. Review.</citation>
    <PMID>27463613</PMID>
  </reference>
  <reference>
    <citation>Bellando-Randone S, Matucci-Cerinic M. Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions. Curr Rheumatol Rep. 2017 Sep 18;19(10):65. doi: 10.1007/s11926-017-0684-2. Review.</citation>
    <PMID>28921059</PMID>
  </reference>
  <reference>
    <citation>Boutou AK, Pitsiou GG, Siakka P, Dimitroulas T, Paspala A, Sourla E, Chavouzis N, Garyfallos A, Argyropoulou P, Stanopoulos I. Phenotyping Exercise Limitation in Systemic Sclerosis: The Use of Cardiopulmonary Exercise Testing. Respiration. 2016;91(2):115-23. doi: 10.1159/000442888. Epub 2016 Jan 6.</citation>
    <PMID>26731293</PMID>
  </reference>
  <reference>
    <citation>Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum. 2004 Oct 15;51(5):805-9. Erratum in: Arthritis Rheum. 2005 Apr 15;53(2):303.</citation>
    <PMID>15478150</PMID>
  </reference>
  <reference>
    <citation>Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003 Jun 9;1:20. Review.</citation>
    <PMID>12831398</PMID>
  </reference>
  <reference>
    <citation>Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology (Williston Park). 1995 Nov;9(11 Suppl):47-60. Review.</citation>
    <PMID>8608056</PMID>
  </reference>
  <reference>
    <citation>Coulter CL, Scarvell JM, Neeman TM, Smith PN. Physiotherapist-directed rehabilitation exercises in the outpatient or home setting improve strength, gait speed and cadence after elective total hip replacement: a systematic review. J Physiother. 2013 Dec;59(4):219-26. doi: 10.1016/S1836-9553(13)70198-X. Review.</citation>
    <PMID>24287215</PMID>
  </reference>
  <reference>
    <citation>Crosby CA, Wehbé MA, Mawr B. Hand strength: normative values. J Hand Surg Am. 1994 Jul;19(4):665-70.</citation>
    <PMID>7963331</PMID>
  </reference>
  <reference>
    <citation>de Oliveira NC, Portes LA, Pettersson H, Alexanderson H, Boström C. Aerobic and resistance exercise in systemic sclerosis: State of the art. Musculoskeletal Care. 2017 Dec;15(4):316-323. doi: 10.1002/msc.1185. Epub 2017 Apr 5. Review.</citation>
    <PMID>28378937</PMID>
  </reference>
  <reference>
    <citation>Dechman G, Scherer SA. Outcome Measures in Cardiopulmonary Physical Therapy: Focus on the Glittre ADL-Test for People with Chronic Obstructive Pulmonary Disease. Cardiopulm Phys Ther J. 2008 Dec;19(4):115-8.</citation>
    <PMID>20467508</PMID>
  </reference>
  <reference>
    <citation>Duruöz MT, Poiraudeau S, Fermanian J, Menkes CJ, Amor B, Dougados M, Revel M. Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol. 1996 Jul;23(7):1167-72.</citation>
    <PMID>8823687</PMID>
  </reference>
  <reference>
    <citation>Fernandes-Andrade AA, Britto RR, Soares DCM, Velloso M, Pereira DAG. Evaluation of the Glittre-ADL test as an instrument for classifying functional capacity of individuals with cardiovascular diseases. Braz J Phys Ther. 2017 Sep - Oct;21(5):321-328. doi: 10.1016/j.bjpt.2017.06.001. Epub 2017 Jul 3.</citation>
    <PMID>28711380</PMID>
  </reference>
  <reference>
    <citation>Ganderton L, Jenkins S, Gain K, Fowler R, Winship P, Lunt D, Gabbay E. Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial. BMC Pulm Med. 2011 May 23;11:25. doi: 10.1186/1471-2466-11-25.</citation>
    <PMID>21600062</PMID>
  </reference>
  <reference>
    <citation>Ingegnoli F, Boracchi P, Ambrogi F, Gualtierotti R, Galbiati V, Meroni PL. Hand impairment in systemic sclerosis: association of different hand indices with organ involvement. Scand J Rheumatol. 2010;39(5):393-7. doi: 10.3109/03009741003629028.</citation>
    <PMID>20476855</PMID>
  </reference>
  <reference>
    <citation>Justo AC, Guimarães FS, Ferreira AS, Soares MS, Bunn PS, Lopes AJ. Muscle function in women with systemic sclerosis: Association with fatigue and general physical function. Clin Biomech (Bristol, Avon). 2017 Aug;47:33-39. doi: 10.1016/j.clinbiomech.2017.05.011. Epub 2017 May 26.</citation>
    <PMID>28575704</PMID>
  </reference>
  <reference>
    <citation>Khanna D, Kowal-Bielecka O, Khanna PP, Lapinska A, Asch SM, Wenger N, Brown KK, Clements PJ, Getzug T, Mayes MD, Medsger TA, Oudiz R, Simms R, Steen V, Maranian P, Furst DE. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S33-9. Epub 2011 May 16.</citation>
    <PMID>21586216</PMID>
  </reference>
  <reference>
    <citation>Lima TRL, Kasuki L, Gadelha M, Lopes AJ. Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study. Endocrine. 2019 Nov;66(2):301-309. doi: 10.1007/s12020-019-02011-x. Epub 2019 Jul 17.</citation>
    <PMID>31317523</PMID>
  </reference>
  <reference>
    <citation>Gasho CJ, Torralba KD, Chooljian DM, Cohen A, Dinh VA. Impact of a lung ultrasound course for rheumatology specialists (IMPACT-2). Clin Exp Rheumatol. 2019 May-Jun;37(3):380-384. Epub 2018 Aug 29.</citation>
    <PMID>30183605</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Gargani L, Barskova T, Furst DE, Cerinic MM. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther. 2017 Sep 18;19(1):206. doi: 10.1186/s13075-017-1409-7. Review.</citation>
    <PMID>28923086</PMID>
  </reference>
  <reference>
    <citation>Landim SF, Bertolo MB, Marcatto de Abreu MF, Del Rio AP, Mazon CC, Marques-Neto JF, Poole JL, de Paiva Magalhães E. The evaluation of a home-based program for hands in patients with systemic sclerosis. J Hand Ther. 2019 Jul - Sep;32(3):313-321. doi: 10.1016/j.jht.2017.10.013. Epub 2017 Dec 1.</citation>
    <PMID>29198478</PMID>
  </reference>
  <reference>
    <citation>Levis AW, Harel D, Kwakkenbos L, Carrier ME, Mouthon L, Poiraudeau S, Bartlett SJ, Khanna D, Malcarne VL, Sauve M, van den Ende CH, Poole JL, Schouffoer AA, Welling J, Thombs BD; the Scleroderma Patient-Centered Intervention Network Investigators. Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1704-1713. doi: 10.1002/acr.22893. Epub 2016 Oct 9.</citation>
    <PMID>27015290</PMID>
  </reference>
  <reference>
    <citation>Li L, Cui Y, Chen S, Zhao Q, Fu T, Ji J, Li L, Gu Z. The impact of systemic sclerosis on health-related quality of life assessed by SF-36: A systematic review and meta-analysis. Int J Rheum Dis. 2018 Nov;21(11):1884-1893. doi: 10.1111/1756-185X.13438. Epub 2018 Nov 14.</citation>
    <PMID>30428506</PMID>
  </reference>
  <reference>
    <citation>Lima TR, Guimarães FS, Carvalho MN, Sousa TL, Menezes SL, Lopes AJ. Lower limb muscle strength is associated with functional performance and quality of life in patients with systemic sclerosis. Braz J Phys Ther. 2015 Mar-Apr;19(2):129-36. doi: 10.1590/bjpt-rbf.2014.0084. Epub 2015 Mar 13.</citation>
    <PMID>25789555</PMID>
  </reference>
  <reference>
    <citation>Lopes AJ, Capone D, Mogami R, Menezes SL, Guimarães FS, Levy RA. Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. J Bras Pneumol. 2011 Mar-Apr;37(2):144-51. English, Portuguese.</citation>
    <PMID>21537649</PMID>
  </reference>
  <reference>
    <citation>Lopes AJ, Justo AC, Ferreira AS, Guimaraes FS. Systemic sclerosis: Association between physical function, handgrip strength and pulmonary function. J Bodyw Mov Ther. 2017 Oct;21(4):972-977. doi: 10.1016/j.jbmt.2017.03.018. Epub 2017 Mar 29.</citation>
    <PMID>29037654</PMID>
  </reference>
  <reference>
    <citation>Maddali-Bongi S, Del Rosso A. Systemic sclerosis: rehabilitation as a tool to cope with disability. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):162-169. Epub 2016 Jul 4. Review.</citation>
    <PMID>27384349</PMID>
  </reference>
  <reference>
    <citation>Mitropoulos A, Gumber A, Crank H, Akil M, Klonizakis M. The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis patients. Arthritis Res Ther. 2018 Jun 5;20(1):112. doi: 10.1186/s13075-018-1605-0.</citation>
    <PMID>29871697</PMID>
  </reference>
  <reference>
    <citation>Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal Manifestations of Systemic Sclerosis. Rheum Dis Clin North Am. 2015 Aug;41(3):507-18. doi: 10.1016/j.rdc.2015.04.011. Epub 2015 May 26. Review.</citation>
    <PMID>26210132</PMID>
  </reference>
  <reference>
    <citation>Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, Celermajer D, Zochling J, Proudman S, Nikpour M; Australian Scleroderma Interest Group (ASIG). Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther. 2017 Jun 2;19(1):122. doi: 10.1186/s13075-017-1341-x.</citation>
    <PMID>28576149</PMID>
  </reference>
  <reference>
    <citation>Mouthon L, Mestre-Stanislas C, Bérezné A, Rannou F, Guilpain P, Revel M, Pagnoux C, Guillevin L, Fermanian J, Poiraudeau S. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2010 Jan;69(1):214-7. doi: 10.1136/ard.2008.094193.</citation>
    <PMID>19221115</PMID>
  </reference>
  <reference>
    <citation>Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D. Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.</citation>
    <PMID>29381834</PMID>
  </reference>
  <reference>
    <citation>Paik JJ, Wigley FM, Mejia AF, Hummers LK. Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1695-1703. doi: 10.1002/acr.22870. Epub 2016 Oct 9.</citation>
    <PMID>26881982</PMID>
  </reference>
  <reference>
    <citation>Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.</citation>
    <PMID>29207002</PMID>
  </reference>
  <reference>
    <citation>Racine M, Hudson M, Baron M, Nielson WR; Canadian Scleroderma Research Group. The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. J Pain Symptom Manage. 2016 Jul;52(1):43-53. doi: 10.1016/j.jpainsymman.2015.12.314. Epub 2016 Feb 11.</citation>
    <PMID>26876159</PMID>
  </reference>
  <reference>
    <citation>Rannou F, Poiraudeau S, Berezné A, Baubet T, Le-Guern V, Cabane J, Guillevin L, Revel M, Fermanian J, Mouthon L. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum. 2007 Feb 15;57(1):94-102.</citation>
    <PMID>17266096</PMID>
  </reference>
  <reference>
    <citation>Ranque B, Authier FJ, Berezne A, Guillevin L, Mouthon L. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci. 2007 Jun;1108:268-82. Review.</citation>
    <PMID>17899625</PMID>
  </reference>
  <reference>
    <citation>Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, Launay D, Hachulla E, Kahan A, Cabane J, Gherardi R, Guillevin L, Mouthon L. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis. 2009 Sep;68(9):1474-7. doi: 10.1136/ard.2008.095919. Epub 2008 Dec 3.</citation>
    <PMID>19054827</PMID>
  </reference>
  <reference>
    <citation>Reis CMD, Karloh M, Fonseca FR, Biscaro RRM, Mazo GZ, Mayer AF. Functional capacity measurement: reference equations for the Glittre Activities of Daily Living test. J Bras Pneumol. 2018 Sep-Oct;44(5):370-377. doi: 10.1590/S1806-37562017000000118. Epub 2018 Jul 16. English, Portuguese.</citation>
    <PMID>30020345</PMID>
  </reference>
  <reference>
    <citation>Salaffi F, Di Carlo M, Carotti M, Farah S, Ciapetti A, Gutierrez M. The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Biomed. 2019 Jan 15;89(4):541-557. doi: 10.23750/abm.v89i4.7298.</citation>
    <PMID>30657123</PMID>
  </reference>
  <reference>
    <citation>Sandqvist G, Eklund M, Akesson A, Nordenskiöld U. Daily activities and hand function in women with scleroderma. Scand J Rheumatol. 2004;33(2):102-7.</citation>
    <PMID>15163111</PMID>
  </reference>
  <reference>
    <citation>Schorpion A, Shenin M, Neubauer R, Derk CT. A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis. BMC Rheumatol. 2018 May 15;2:13. doi: 10.1186/s41927-018-0021-z. eCollection 2018.</citation>
    <PMID>30886964</PMID>
  </reference>
  <reference>
    <citation>Skumlien S, Hagelund T, Bjørtuft O, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. Respir Med. 2006 Feb;100(2):316-23. Epub 2005 Jun 6.</citation>
    <PMID>15941658</PMID>
  </reference>
  <reference>
    <citation>Sultan N, Pope JE, Clements PJ; Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford). 2004 Apr;43(4):472-8. Epub 2003 Dec 16.</citation>
    <PMID>14679295</PMID>
  </reference>
  <reference>
    <citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.</citation>
    <PMID>24092682</PMID>
  </reference>
  <reference>
    <citation>Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol. 2014 Apr;10(4):200-2. doi: 10.1038/nrrheum.2014.22. Epub 2014 Feb 18.</citation>
    <PMID>24535544</PMID>
  </reference>
  <reference>
    <citation>Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007 Jun;66(6):754-63. Epub 2007 Jan 18.</citation>
    <PMID>17234652</PMID>
  </reference>
  <reference>
    <citation>Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005 Oct;44(10):1212-6. Epub 2005 May 3. Review.</citation>
    <PMID>15870151</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <keyword>Physical Therapy</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Functional capacity</keyword>
  <keyword>Exercise</keyword>
  <keyword>ADL-Glittre test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

